Cardiovascular disease risk is higher for people with hepatitis C
D:A:D study: long-term treatment with tenofovir associated with increased risk of serious liver disease
High rates of modifiable cancer risk factors present in Western HIV-positive patients
Hepatitis C virus linked to increased risk of Parkinson's disease, studies show
DAAs could halt HCV epidemic in US – but only with near-universal testing and big increase in treatment rates
A quarter of people with HCV initially refused access to sofosbuvir/lepidasvir, says US study, but most successfully appeal
Sofosbuvir/daclatasvir combination could be produced for $200 per hepatitis C cure
Grazoprevir/elbasvir cures more than 90% of people with HIV/HCV co-infection
